Cost-Effectiveness of Vedolizumab for the Treatment of Adult Patients with Moderately-to-Severely Active Ulcerative Colitis in Russia

BACKGROUND: Vedolizumab is one of the biologic drugs recommended by current clinical guidelines for the treatment of moderately-to-severely active ulcerative colitis (UC) in Russia. OBJECTIVES: To estimate the cost-effectiveness of vedolizumab compared with alternative strategies in the management o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Value in health 2017-10, Vol.20 (9), p.A635
Hauptverfasser:	Pyadushkina, E, Derkach, EV
Format:	Artikel
Sprache:	eng
Schlagworte:	Adults Clinical practice guidelines Cost analysis Health care expenditures Inflammatory bowel disease Infliximab Medical treatment Monoclonal antibodies Patients Quality adjusted life years Remission Remission (Medicine) Side effects Surgery Tumor necrosis factor-α Ulcerative colitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!